A CRISPR-mediated knockdown of FABP4 resulted in a significant decrease in the metastatic tumour burden and FABP4 inhibition using BMS309403-sensitised ovarian cancer cells to carboplatin, indicating that lipid uptake mediated by FABP4 contributes to chemoresistance in this system [37,38]. The gene discussed is FABP4; the disease is neoplasm.